ISSN:
1420-908X
Source:
Springer Online Journal Archives 1860-2000
Topics:
Medicine
Notes:
Abstract Bucillamine [SA96: N-(2-mercapto-2-methylpropanoyl)-l-cysteine], a synthetic SH compound, has recently been developed as remission-inducing agent for rheumatoid arthritis (RA), and its clinical usefulness for RA has been proved in Japan. Bucillamine suppressed the mitogen-induced proliferation of murine lymphocytesin vitro. The present study was undertaken to clarify the effect of bucillamine primarily on the release of interleukin (IL)-1 from monocytes and on the proliferation of T cells. Bucillamine significantly inhibited IL-1-induced thymocyte proliferation in a dose-dependent manner. And, bucillamine also inhibited IL-2-induced proliferation at the concentration of 1×10−4 M, but augmented proliferation at the concentration of 1×10−5 M. In contrast,d-penicillamine (an analogous SH compound to bucillamine) did not show any significant effect at similar concentrations.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/BF01997621
